US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
| LUPKYNIS | 7.9MG | capsule · oral | AURINIA | Prescription | 22 Jan 2021 |
EMA European Union — centrally authorised medicines
Lupkynis Otsuka Pharmaceutical Netherlands B.V. · Authorised · authorised 15 Sep 2022 · ATC L04AD03
Therapeutic indication (EMA)
Lupkynis is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class III, IV or V (including mixed class III/V and IV/V) lupus nephritis (LN).
Luveniq Lux Biosciences GmbH · Application withdrawn · ATC L04AD03
Therapeutic indication (EMA)
treatment of non-infectious uveitis
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.